- Report
- August 2022
- 91 Pages
Middle East, Africa
From €1374EUR$1,500USD£1,170GBP
- Report
- August 2022
- 91 Pages
Asia Pacific
From €1374EUR$1,500USD£1,170GBP
- Report
- August 2022
- 81 Pages
North America
From €1374EUR$1,500USD£1,170GBP
- Report
- August 2022
United States
From €1777EUR$1,940USD£1,513GBP
- Report
- August 2022
Global
From €723EUR$790USD£616GBP
- Report
- August 2021
Global
From €3654EUR$3,990USD£3,111GBP
- Report
- May 2022
- 95 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$4,094USD£3,084GBP
- Report
- November 2022
- 108 Pages
Global
From €1832EUR$2,000USD£1,559GBP
Gaucher Disease is a rare genetic disorder caused by the deficiency of an enzyme called glucocerebrosidase. This enzyme is responsible for breaking down a fatty substance called glucocerebroside, which accumulates in the cells of the body, leading to a variety of symptoms. Treatment for Gaucher Disease includes enzyme replacement therapy, substrate reduction therapy, and chaperone therapy.
The Gaucher Disease Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat Gaucher Disease, such as enzyme replacement therapy, substrate reduction therapy, and chaperone therapy. These drugs are used to reduce the symptoms of Gaucher Disease and improve the quality of life of those affected.
Some companies in the Gaucher Disease Drug market include Sanofi, Shire, Pfizer, and Genzyme. Show Less Read more